This case report suggests that combined PD-1/CTLA-4 immune checkpoint inhibitor therapy may be effective in some patients with HNSCC, but further research is needed to confirm its efficacy and safety. This evidence concerns the gene CTLA4 and head and neck squamous cell carcinoma.